Supplemental material, "Extended dosing intervals of ixekizumab for psoriasis: a single-center, uncontrolled, prospective study"

Description

Supplemental Fig 1. An overview of study design. The recommended doses regimen is 160 mg at the first administration and then 80 mg at week 2, 4, 6, 8,10, and 12, followed by monthly maintenance dosing. The adjusted doses regimen is 160 mg at the first administration and then 80 mg at week 2, 4 and 8, followed by maintenance dosing every 8 weeks. Only one patient discontinued IXE treatment due to the treatment-unrelated cause which was the recurrence of lung cancer. 29, 20, 9 and 2 patients simply entered the study too late to make it to 32, 24, 16 and 8 weeks by the end of the study, respectively. Supplemental Table I. Adverse events in the total patient population. Data are expressed as absolute number (percentage).

Categories

Licence